CliffBio
small molecule

ORFADIN

NITISINONE

Loss of exclusivity—loss of exclusivity
CompanySWEDISH ORPHAN BIOVITRUM AB PUBL

Drug detail

Brand nameORFADIN
Active ingredientNITISINONE
Strength20MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusRX

More from SWEDISH ORPHAN BIOVITRUM AB PUBL

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ORFADIN patent cliff — loss of exclusivity — | CliffBio